Appendix 1.

Inclusion criteria.

Process	Criteria
P (Patient Population)	Human adults (≥18 years) cancer patients receiving highly or moderately emetogenic chemotherapy
I (Intervention or Exposure)	Studies assessing the efficacy or safety of one of the following antiemetics: 5-HT3s: palonosetron, ondansetron, granisetron, tropisetron, dolasetron, metoclopramide, ramosetron NK1s: aprepitant, fosaprepitant, casopitant, ezlopitant, netupitant, vestipitant Other: Olanzapine, levonantradol, lorazepam, nabilone, dronabinol, dexamethasone
C (Comparators)	Placebo or active comparator
O (Outcomes)	At least complete response, defined as no emesis/vomiting and no rescue medication Complete protection, partial response, complete control, total control, time to first emetic episode, time to use of rescue medication, time to treatment failure
S (Study Design)	Blinded, randomised controlled trials (≥ Phase 2) with more than 50 patients

5-HT3: 5-HT3 receptor antagonist; NK1: NK1 receptor antagonist.